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Introduction
CG Barnes
President of the International Society for Behçet’s Disease (ISBD),
formerly Department of Rheumatology, The Royal London Hospital, UK
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For this meeting of two Working Groups of the ISBD, the back-
ground to our present knowledge is reviewed, including the follow-
ing: the original description of Behçet’s disease (BD) by
Hippocrates in the 5th century BC and the 20th century description
with the adoption of the eponymous title of ‘Behçet’s disease’; the
lack of a specific diagnostic test but noting the pathergy test and
the association with HLA-B51; description of the multisystem man-
ifestations of the disease and the prevalence of these manifesta-
tions, including the differences in different parts of the world; and
the pathological classification of BD as a vasculitis.
Nevertheless the diagnosis and classification of the condition
depends on the acumen of the physician in diagnosis of the individ-
ual patient in the routine clinical situation, and the classification of
groups of patients with the disease for inclusion into clinical
studies and trials. The older ‘diagnostic schemes’ (e.g. Japanese,
Mason and Barnes, O’Duffy, Dilsen) should be discarded and the
International Classification of BD used as an entry criterion for clin-
ical studies and trials.
The natural history of BD still requires further study with particular
reference to being able to predict the type of disease (mucocuta-
neous, ocular, neuro, etc.), the localization of manifestations, the
likelihood of recurrences and their duration, and the overall severity
of the disease in the individual patient.
Basic research – pathogenesis (?bacterial), immunology (e.g.
CD4+CD28– T cells) and gender association (prevalence, severity
and response to treatment) – must continue and may proceed
more quickly if coordinated on a multicentre, multinational basis.
Therapeutic trials continue but to date there are surprisingly few
controlled studies (e.g. colchicine, azathioprine and interferon-α). It
is imperative that future trials be properly controlled, and open
trials reserved for very preliminary ‘pilot’ studies. Controlled trials
(either single or double blind; versus placebo or other comparison
drug) are required at present, in particular for the following: IFN-α –
optimum dosage regimen with regard to both efficacy and toler-
ance (side effects); anti-TNF-α, and possibly of antibiotics. Again
these may be progressed faster on a coordinated multicentre,
multinational basis but with the prior determination of updated
entry criteria and outcome measures.
The ISBD, as a medical research society, and through its Working
Groups, should be a vehicle for the organization and coordination
of studies – single centre, multicentre in a single country, or multi-
centre on a multinational basis. The Working Groups for Clinical
Trials and Treatment and for Basic Research should work towards
the coordination of clinical studies and trials with agreed entry cri-
teria – diagnostic classification and disease manifestations and
activity; outcome measures; and protocols, including statistical
methodology. Multinational coordination through the ISBD may
lead to the necessary availability of appropriate funding and secre-
tarial assistance for such trials and studies.
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Perspectives of the Working Group on Drug Trials
including Collaborative Trials of the ISBD and
rationale for new clinical trials
S Assaad-Khalil
Head of the Working Group, University Hospital, Alexandria, Egypt
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The goals of the working group are to contact and recruit
members; to contact other working groups and propagate their
work particularly in the context of established criteria of diagnosis
and disease activity in Behçet’s disease (BD); to exchange experi-
ence via direct contact, home page, journal and/or newsletter; to
plan collaborative trials; to contact pharmaceutical companies and
research institutes for possible cooperation in clinical trials; to
prepare a workshop on clinical trials at ISBD congresses; and to
support and alert patients concerning treatment modalities.
Additional clinical trials are needed. From both the physicians’ and
the patients’ perspective, current therapy does not satisfy the goals
of treatment (e.g. preventing blindness in ocular BD, preventing
morbidity and mortality of neurologic and vascular events, improving
the quality of life). Serious adverse effects may result from current
therapies. Professor S Assaad-Khalil reported the results of a retro-
spective evaluation of therapeutic agents commonly used in BD,
which he had recently carried out in 127 patients (110 males, 17
females; 20–65 years old) randomly selected from the Alexandria
BD registry to assess the efficacy of different therapeutic agents in
daily practice for a mean duration of 11.07 years by the same group
of observers. A special focus was made on the ocular sequelae of
the disease, with detailed ocular documentation carried out in 254
eyes (visual acuity, intraocular pressure, state of the lens, presence
of uveitis, retinal vessels and optic nerve). Of BD patients 16.6%
lost effective vision and another 17.6% of the patients had reduced
vision lower than 6/60. Uveitis was found in 37.4%, lens opacity in
44.9%, retinal vessel affection occurred in 23.3% and optic nerve
affection in 29.9%. In conclusion, it can be seen that eye sequelae
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are still very devastating in BD, with a delay in diagnosis having a
significant deleterious effect on the outcome of the disease. There
is still no ideal therapeutic regimen resulting in full remission of BD
and preventing its sequelae. At present, combination therapy seems
to be the most appropriate approach when considering efficacy and
safety. However, there is a great need for a controlled and masked
multicentre trial to re-evaluate the efficacy and safety of the different
therapeutic modalities on a long term basis.
Investigators must continue to have strong ethical commitments to
patients in designing clinical trials. Trials serving patients, patients’
life, health and well-being is our goal. There should be actual repre-
sentation of the patients in the design of the clinical trials. A
prospective study design, predetermined specific primary end-
points and blinding should ensure the integrity of the study.
Improvement should be quantified as objectively and accurately as
possible, putting into consideration patient’s quality of life, and
measuring all adverse effects. Statistics should depend on strict
criteria for statistical significance, avoiding post hoc analysis.
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Cytotoxic drugs in ocular lesions of Behçet’s disease
F Davatchi, F Shahram, H Chams, A Nadji, AR Jamshidi, 
C Chams, M Akbarian, F Gharibdoost, M Sedigh, B Sadeghi
Behçet’s Unit, Rheumatology Research Center, Tehran University for
Medical Sciences, Tehran, Iran
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Introduction Cytotoxic drugs are the first line treatment for
ophthalmologic manifestations of Behçet’s disease (BD) despite
the advent of the new biological agents. The latter are to be used
in intractable inflammatory attacks as they seem to be efficient in a
few case studies. Cytotoxic drugs are affordable, easy to use,
effective and safe, even in long-term use. They have to be com-
bined to steroids (0.5 mg prednisolone/kg per day as attack dose,
then tapering gradually to the patient’s need). All the cytotoxic
drugs used were effective (ACR 1966, APLAR 2000).
As all treatment methods with cytotoxic drugs were efficient and
had approximately the same efficiency (percentage of eyes with
improved VA), all data were pulled together. The advantage to put
the data together was to show the result of treatment in long run in
real life. Some patients who were resistant to the given treatment
were switched to another treatment and if again ineffective to a
third or forth treatment. In pulled data the results before the first
treatment were compared with those after the last treatment.
Materials and methods Patients who had an active posterior uveitis
and/or retinal vasculitis were selected for this study. They were 978
patients. Among them, 277 received more than one treatment. The
mean duration of eye lesions was 54 months (SD 42.1), with the
maximum duration 271 months. The mean follow-up time was
52 months (SD 40.8) with the maximum of follow up 261 months.
Comparison was made by the Student paired t test. VA was calculated
on a Snellen chart on a scale of 10 on 10. The Activity Indexes (AI) for
different compartment of eyes were calculated according to Ben Ezra.
Results The mean VA of all eyes was 3.8. It improved to 4.7 after the
treatment (t 9.544, P< 0.000001). Improved eyes were 52%, 18%
were unchanged, and 30% were aggravated. The mean AI of anterior
uveitis improved from 2.5 to 0.8 (t 18.595, P< 0.000001). Improved
eyes were 77%, 4% were unchanged, and 19% were aggravated.
The mean AI of posterior uveitis improved from 2.1 to 0.9 (t 27.039,
P< 0.000001). Improved eyes were 74%, 10% were unchanged,
and 16% were aggravated. The mean AI of retinal vasculitis improved
from 2.5 to 1.4 (t 11.661, P< 0.000001). Improved eyes were 62%,
12% were unchanged, and 26% were aggravated.
To see if the cytotoxic drugs maintained their efficacy over the time,
patients were divided in different groups according to their treat-
ment duration. The percentage of improved eyes remained the
same, even in the group of patients where the duration of treatment
exceeded 9 years.
Conclusion The least improved parameter was the visual acuity,
which reflects not only the inflammatory index of the eye, but also
the chronicity index (cataract, vitreous organization, hemorrhage,
vessel necrosis of retina, neovascularization, and optic nerve
atrophy). Seventy percent of the eyes improved or maintained their
VA, which is quite remarkable for this disease.
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The use of interferon-alfa in Behçet’s disease:
review of the literature
I Kötter, I Günaydin, M Zierhut, N Stübiger
University Hospital, Dept. of Internal Medicine II and Ophthalmology II,
Tübingen, Germany
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Objective To evaluate the efficacy and safety of interferon-alfa for
the treatment of Behçet’s disease and discuss its possible mecha-
nisms of action.
Methods Reports published until July 2002 in all languages were
identified by the PubMed database and the Behçet’s disease con-
ference proceedings and abstract booklets. The indexing items
used were Behçet and interferon.
Results Thirty-two original reports and four selected abstracts
were included in the analysis. Systemic IFN-alfa was administered
to 405 patients. Two hundred and sixteen patients with acute
ocular disease were treated with IFN-alfa. Two hundred and ninety
eight patients received IFN-alfa2a and 141 IFN-alfa2b. 85.6% of
the patients with mucocutaneous symptoms, 95.8% with arthritis
and 95.6% with uveitis exhibited a partial or complete response.
Higher IFN doses were more effective than low dose regimens and
led up to 56% long term remissions after discontinuation of IFN-
alfa. IFN-alfa2a apparently was superior to IFN-alfa2b with more
complete remissions, but this probably was due to a bias caused
by the larger number of patients treated with IFN-alfa2a. Side
effects were dose dependent and similar to those occurring in
patients with hepatitis C.
Conclusions Although the comparability of the studies is ham-
pered due to different study designs, it can be concluded that IFN-
alfa is effective for the treatment of BD. It was effective even in
resistant posterior uveitis, where long-term remissions with preser-
vation of visual acuity could be achieved. In contrast, for mucocuta-
neous symptoms, only partial remissions were reported.
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Efficacy of recombinant human interferon-alfa2a
on ocular and extra-ocular manifestations of
Behçet’s disease and influence on cells of the
immune system: results of an open four center trial
I Kötter, M Treusch, R Vonthein, M Zierhut, A Eckstein, T Ness, 
I Günaydin, B Grimbacher, S Blaschke, HH Peter, N Stübiger
University Hospital, Department of Internal Medicine II and
Ophthalmology II, Tübingen, Germany
Arthritis Res Ther 2003 5(Suppl 2):5 (DOI 10.1186/ar980)
Background Behçet’s disease (BD) is a multisystem vasculitis of
unknown origin. Standard treatment comprises systemic immunosup-
pressive agents. In a study primarily designed for refractory ocular
disease we additionally evaluated the efficacy of recombinant human
interferon-alpha2a (rhIFN-alpha2a) for the extraocular manifestations.
Method Fifty patients were included in the study. rhIFN-alpha2a
was applied at a dose of 6 million units subcutaneously daily. Dose
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reduction was performed according to a decision tree until discon-
tinuation. Disease activity was evaluated by the Behçet’s disease
activity scoring system and the uveitis scoring system. In parallel,
peripheral blood mononuclear cells (PBMC) from 14 patients and
10 healthy controls were isolated, stained with four different fluo-
rescent dyes and measured with a fluorescence activated cell
sorter (FACS). Statistical analysis was performed by ANCOVA and
Welsh test.
Results Response rate of the ocular manifestations was 92%.
Visual acuity rose significantly from 0.56 to 0.84 at week 24
(P < 0.0001). Posterior uveitis score of the affected eyes fell by
46% in 1 week (P < 0.001). Mean BD activity score fell in a dose-
dependent fashion by 1.2 points in the first week (P < 0.0001) and
from 5.8 to 3.3 at week 24. After a mean observation period of
36.4 months, 17 patients are off treatment and disease free for
29.5 months (mean). In the other patients maintenance dosage is
3 million units 3 times weekly. Whereas extraocular manifestations
such as genital ulcerations, arthritis and skin lesions remitted under
IFN, this was the case only for 36% of oral aphthous ulcers. The
lymphocyte subpopulations showed a significant increase of γδ
positive T cells and NK cells in the patients before treatment when
compared with healthy controls. Under IFN treatment, they
decreased significantly and almost reached the level of the control
group. Additionally, monocytes and B cells increased.
Conclusion rhIFN-alpha2a is effective in ocular BD, resulting in
significant improvement in vision and complete remission of ocular
vasculitis in the majority of the patients. It is also effective for the
extraocular manifestations of the disease, although less so for oral
aphthous ulcers. A participation of γδ positive T cells and NK cells
in the pathogenesis of BD is implicated; their decrease may explain
the mechanism by which IFN-alpha exerts its therapeutic effects,
whereas the increase of monocytes and B cells may be responsi-
ble for side effects of IFN such as flu-like syndrome and autoim-
mune phenomena.
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TNF and anti-TNF agents in Behçet’s disease
KT Calamia
Mayo Clinic Jacksonville, Jacksonville, FL, USA
Arthritis Res Ther 2003 5(Suppl 2):6 (DOI 10.1186/ar981)
The rapid response and effectiveness of anti-TNF agents in the
treatment of many immune mediated inflammatory disorders draws
comparison to the response of rheumatoid arthritis to cortisone, first
witnessed over 50 years ago by Philip Hench and colleagues at the
Mayo Clinic. It is now known that many of the anti-inflammatory
effects of corticosteroids are due to their inhibition of TNF produc-
tion. A new dimension of efficacy is possible with TNF agents,
however, in that inhibition of disease progression is now possible.
Might these agents be considered the corticosteroids of the new
millennium? Like rheumatoid arthritis and Crohn’s disease, Behçet’s
disease is believed to be associated with a Th1-mediated immune
response. Increased levels of TNF-α are found in Behçet’s disease
and has provided support for the empiric use of anti-TNF-α thera-
pies used in a number of published cases and small case series.
Hassard (2001) reported rapid and dramatic improvement in gas-
trointestinal and extraintestinal symptoms and findings of the disor-
der after treatment with infliximab. Similar response was seen in
two other patients treated by Travis (2001). This experience was
followed by the report of Robertson (2001) of a patient free of oral
and genital ulcerations for the first time in 10 years after three infu-
sions of infliximab. Remission of mucocutaneous symptoms for one
year followed two infusions of infliximab in a patient previously
uncontrolled by multiple immunosuppressive agents (Goossens,
2001). Mucocutaneous lesions remitted with infliximab in a patient
with Behçet’s disease associated with rheumatoid arthritis (Rozen-
baum, 2002). At EULAR 2002, Turkish investigators reported the
results of the first double-masked, placebo-controlled study
(n = 40) of anti-TNF therapy with etanercept in mucocutaneous
Behçet’s disease (Melikoglu, 2002). This agent suppressed
disease manifestations with resurgence after the drug was discon-
tinued. Additional recent reports of anti-TNF therapies in Behçet’s
disease were presented at several international meetings.
The experience with anti-TNF-α treatments for the ocular manifes-
tations of Behçet’s disease has been growing and very positive.
Sfikakis (2001) reported the benefits of infliximab in five patients
with panuveitis in Behçet’s disease. This included two patients
treated with infliximab therapy without an increase in conventional
treatment. At the ACR meeting in 2002 these Greek investigators
reported successful monotherapy with infliximab in acute ocular
inflammation in Behçet’s disease in 14 patients. The authors sug-
gested that the dramatic and rapid response in these patients
would favor the use of this agent over conventional therapy. Posi-
tive responses to anti-TNF agents in ocular Behçet’s disease have
been documented in numerous case reports in the literature or pre-
sentations at international meetings.
Significant differences exist between currently available anti-TNF-α
agents, including mechanism of TNF-α inhibition, avidity, half life,
immunogenicity, ability to bind lymphotoxin (TNF-β), ability to bind
membrane bound TNF-α, as well as the mode and frequency of
administration. One or more of these differences may account for
the variable efficacy of these agents in certain diseases, such as
Crohn’s disease, and the variable side-effect profile of these drugs.
We believe that it is appropriate to study all available agents, includ-
ing adalimumab, for their efficacy and safety in Behçet’s disease.
The efficacy of these new biologic agents for the more serious man-
ifestations of Behçet’s disease, in particular, should be investigated.
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A review on disease activity scores in Behçet’s
disease (BD)
M Baltaci
Department of Dermatology and Venerology, University of Innsbruck,
Austria
Arthritis Res Ther 2003 5(Suppl 2):7 (DOI 10.1186/ar982)
Currently there are no laboratory markers that correlate well with the
clinical findings in BD. Therefore assessment of disease activity has
to be based on history of clinical features. There have been several
attempts to develop disease activity measurements: (1) the scheme
in use by H Yazici (1984; evaluation depends on features found on
the day the patient attends clinic); (2) the Iranian Behçet’s disease
Dynamic Measure (IBDDAM; F Davatchi 1991; evaluation depends
on accurate history of symptoms up to 12 months prior to the date
of assessment); and (3) the European scheme (1991; initially devel-
oped in the UK by Chamberlain-Barnes-Silman incorporating fea-
tures of the scheme used by H Yazici). In all three forms scoring of
disease activity is based on clinical features only.
In 1994 a workshop was held in Leeds (UK) to arrive at a consen-
sus view about the contents of the activity form with emphasis on
the need for clarity and consistency for potential use by clinicians
worldwide. The Behçet’s Disease Current Activity Form (BDCAF)
was developed, which depends on accurate history of clinical fea-
tures present during the month prior to the date of assessment.
Clinical features in BD vary considerably over time; in order to doc-
ument this variation, new clinical features present over the preced-
ing 28 days are scored. This represents a compromise between
assessing disease activity based on clinical features on day of
assessment, which may be unrepresentative of overall disease
activity and clinical features present over a longer time period, as in
Available online http://arthritis-research.com/supplements/5/S2S4
the IBDDAM, which reduces reliability in terms of accurate recall of
symptoms by patients. In BDCAF disease activity rating for oral
and genital ulceration, and skin lesions relies solely on the duration
of symptoms and does not take into account the size or number of
lesions present (which might also reflect activity).
A study from Bhakta BB et al. (Rheumatology 1999) shows that
the BDCAF is easy to complete and is a reliable method of assess-
ing and documenting clinical activity in BD patients for use in
routine clinical practice, that it has a good interobserver reliability
for general disease activity and that there is difficulty in reliable
scoring of uncommon manifestations such as large vessel involve-
ment, GI inflammation and nervous system involvement.
A Turkish study (Hamuryudan et al.,  Rheumatology 1999) to
examine interobserver and intraobserver reliability of the Turkish
version of BDCAF shows a good intra- and interobserver agree-
ment for orogenital ulcers and eye involvement, a poor agreement
between and within observers for their overall impression and indi-
vidual low kappa scores for erythema nodosum, vascular, CNS and
gastrointestinal involvement. A local disease activity index (Lee ES
et al., Book of Abstracts, 10th International Congress on Behçet’s
disease, Berlin, 2002) was developed by Koreans that attempted
to overcome cultural differences. It also excludes any terms that
could be biased, such as fatigue or headache.
For the future we propose a setting of a general clinical score, an
organ specific clinical score, laboratory assessments and imaging
techniques (like MR for CNS involvement, CT/MR-angiogram, 18F-
FDG-PET for vasculitis, etc.), which enables us to distinguish
between chronic or degenerative changes and active lesions when-
ever possible. Disease related overall damage would be the total of
the cumulative old damage and the damage by active disease.
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Behçet’s disease: from innate to adaptive
immunity
H Direskeneli
Head of the Basic Group, Department of Rheumatology, Marmara
University Medical School, Istanbul, Turkey
Arthritis Res Ther 2003 5(Suppl 2):8 (DOI 10.1186/ar983)
Both innate and adaptive immune systems are activated in Behçet’s
disease (BD) with a proinflammatory and Th1 type cytokine profile.
BD might be linked to a specific, primary immune abnormality with a
genetic mutation effecting an adhesion molecule, a proinflammatory
cytokine/chemokine or a transcription or regulatory factor, which
predisposes to early or more intense neutrophil and T cell
responses. Increased neutrophil responses to urate crystals and
fMLP or superantigen-drived interferon-γ response of T cells
suggest a model with these characteristics, which also explains the
‘pathergy’ or ‘skin urate’ tests. MEFV gene mutations, suggested to
be specific for familial mediterranean fever, which decrease the
expression of an anti-inflammatory protein ‘pyrine’ from neutrophils,
are also described in BD from Turkey.
However, adaptive immune system is also crucial in BD with possibly
both external (streptococcal, HSV) and internal antigens driving the
pathogenic tissue T cell infiltrations. Heat shock proteins 60 and 70
can also activate innate immune system directly with Toll-like recep-
tors 2 and 4 and provide both an early innate activation and pro-
longed T cell response. The diverse manifestations of BD responding
to different therapeutical agents also suggest the role of organ-spe-
cific antigens (retinal-S antigen in uveitis) or genetic predispositions
(factor V Leiden in thrombosis) in different BD clinical subsets.
Better characterization of pathogenic immune cell subsets, sys-
temic and local antigens, and abnormal cell activation mechanisms
may help to develop more specific and less toxic immunotherapeu-
tic approaches to still unsatisfactorily treated BD in the future.
Acknowledgement The studies by the author and his collabora-
tors are supported with grants from Turkish Scientific and Techni-
cal Council (TUBITAK) and Marmara University Research Funds.
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Migration of dendritic cells into the lymphatics: the
Langerhans cell example
N Romani, P Stoitzner, S Ebner, H Stössel, S Holzmann, 
G Ratzinger, P Fritsch
Department of Dermatology and Venerology, University of Innsbruck,
Austria
Arthritis Res Ther 2003 5(Suppl 2):9 (DOI 10.1186/ar984)
Dendritic cells, including Langerhans cells of the epidermis and the
mucous membranes, are key leukocytes for the initiation of adap-
tive immune responses as well as for the maintenance of peripheral
tolerance. In the former regard they may well play an important, but
as yet unrecognized role in the pathogenesis of Behçet’s disease.
Epidermal Langerhans cells may serve as a paradigm for their
counterparts in the mucosae. These cells efficiently take up (micro-
bial) antigens, they process them into immunogenic MHC–peptide
complexes, and they transport this form of antigen to the lymph
nodes via lymphatic vessels. Depending on the milieu where
Langerhans cells have encountered antigen (inflammatory versus
non-inflammatory/steady-state), they make T cells proliferate and
acquire effector functions (immunity) or render them unresponsive
or even delete them (tolerance), respectively. In addition, plasma-
cytoid dendritic cells, a recently characterized type of dendritic
cells, may also directly trigger innate responses (e.g. by secretion
of type I interferons in response to virus). Studying the pathways
and the regulation of dendritic cell migration might help to unravel
a possible involvement of dendritic cells in Behçet’s disease.
We present observations on the physical obstacles that dendritic
cells migrating in the skin have to overcome until they reach dermal
lymphatic vessels. Furthermore, we show that migration is critically
dependent on the function of matrix metalloproteinases, in particu-
lar MMP-2 and MMP-9. It becomes evident that Langerhans cells
indeed carry antigens (including self antigens such as
melanosomes or apoptotoic bodies or tumor antigens such as par-
ticular cytokeratins) through the lymphatics. Given these observa-
tions it may be worth studying Langerhans cells and dermal
dendritic cells in Behçet’s disease.
10
Viral infection of retinal pigment epithelium: a
possible role for initiation of Behçet’s disease
EU Irschick1, HP Huemer2, C Larcher2, R Sgonc3, W Göttinger1
1Department of Ophthalmology, 2Institute for Hygiene and
Sozialmedizin and the 3Institute of Pathophysiology, University of
Innsbruck, Austria
Arthritis Res Ther 2003 5(Suppl 2):10 (DOI 10.1186/ar985)
The in vitro susceptibility of human retinal pigment epithelial cells
(RPE) to representative members of different groups of human
pathogenic viruses was investigated in this study. Subacute viral
infection is known to change the phenotype of infected cells,
thereby causing immune-mediated tissue damage. Downregulation
of cell surface antigens provides a means of long-term survival of
viruses and persistent infection. Therefore the aim of this study was
to investigate the capacity of in vitro infection with viruses and the
expression of different cell surface molecules on human RPE cells
following viral infection with special emphasis on those having
immune regulatory functions. Primary cultures of RPE cells were
infected with various viruses. We found infection with different
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neurotropic viruses, respiratory viruses and enteroviruses whereas
no infection was observed with lymphotropic viruses.
Cytomegalovirus (CMV) downregulated MHC class I antigens on
RPE, whereas coxsackie virus (CVB) and HSV did not alter MHC
class I antigen expression. No induction of class II antigens was
observed in RPE cells infected with CVB, HSV or CMV. Adhesion
molecule ICAM-1 (CD54) was slightly increased after virus infec-
tion and the other cell surface molecules did not alter.
Several common human viruses could infect RPE cells. As even
animal viruses, such as pseudorabies virus, could infect these
cells, it might be possible that transient infections with animal
viruses could act as a trigger for ‘autoimmune’ retinal diseases –
and under certain circumstances like genetic predisposition or
immunologic disorders this could lead to Behçet’s disease in
the eye.
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Regulation of inflammatory CD28– T-helper cells by
HLA class I molecules: a new cellular model for
Behçet’s disease?
C Duftner, C Goldberger, E Märker-Hermann, M Schirmer
Department of Internal Medicine, Innsbruck University Hospital,
Innsbruck, Austria and Department of Rheumatology, University of
Mainz, Germany
Arthritis Res Ther 2003 5(Suppl 2):11 (DOI 10.1186/ar986)
From immunogenetical studies we learnt that Behçet’s disease
(BD) is associated with HLA-B*51, and to a lesser extent with
HLA-B*2702. There may even be a role of MICA genes in the
pathogenesis of BD. Various of these MHC class I molecules can
be recognized by NK receptors on NK and NK-T-cells indepen-
dently from peptides. These NK cell receptors may be activating
(DS) or inhibitory (DL). Interestingly, increased percentages of
CD4+CD16+ and CD4+CD56+ T-cell subsets have already been
described in BD patients.
In patients with rheumatoid arthritis and ankylosing spondylitis,
unusual proinflammatory and cytotoxic CD4+ T cells marked by the
lack of the costimulatory molecule CD28 express stimulatory NK
cell receptors on their surface. In rheumatoid arthritis, MHC class I
recognizing NK receptors are even considered as disease risk
genes. In CD4+CD28– T cells from patients with ankylosing
spondylitis we recently showed functional NK cell features and an
enrichment of these cells in the CD4+CD25+ T-cell compartment
by costimulation with HLA-B27 transfected cells.
We hypothesize that CD4+CD28– T-cells as markers of a chronic
inflammatory process are also elevated in BD patients, express
MHC class I recognizing NK receptors, and thus recognize HLA-
B*51 via NK receptors. This mechanism could explain the chronic-
ity of BD as an MHC class I associated disease.
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Immunosuppressive effects of gemcitabine in the
HSV-induced Behçet’s disease like mouse model
S Sohn, M Lutz, HJ Kwon, G Konwalinka, S Lee, M Schirmer
Department of Dermatology and Laboratory of Cell Biology, Ajou
University, Suwon, Korea; Department of Dermatology, University of
Erlangen, Germany; and Department of Internal Medicine, Innsbruck
University Hospital, Austria
Arthritis Res Ther 2003 5(Suppl 2):12 (DOI 10.1186/ar987)
Objective To study effects and side effects of gemcitabine (2′,2′-
difluorodeoxycytidine, dFdC), a pyrimidine synthesis inhibitor, on
skin lesions of a herpes simplex virus-induced Behçet’s disease
(BD)-like mouse model.
Methods Dose-escalation studies with dFdC were performed in
ICR mice with intraperitoneal application over 5 days. After inocula-
tion of ICR mice with herpes simplex virus and classification as
having BD according to a revised Japanese classification, 18 BD-
mice were randomly assigned to placebo, 0.06 or 0.12 µg of
dFdC/day over 5 days. Serum levels of interleukin (IL)-4, IL-6,
IL-10, tumor necrosis factor-α and interferon-γ were determined
using ELISA assays.
Results After application of 3 µg dFdC over 5 days, alanine amino-
transferase increased (P = 0.032) but all other kidney and liver
parameters were unchanged. In BD mice, 5 days of dFdC treat-
ment with 0.06 or 0.12 µg of dFdC/day resulted in a dose-depen-
dent improvement in cutaneous manifestations by more than 60%
(P = 0.017). There was no significant change in cytokine levels and
none of the cytokine levels correlated with response to treatment.
Conclusion DFdC shows promising effects to improve cutaneous
lesions in the herpes simplex virus-induced BD-like mouse model.
In this animal model, effects of dFdC on the cytokine profile
remained inconclusive.
13
Streptococcal antigen in the pathogenesis of
Behçet’s disease
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Patients with Behçet’s disease (BD) are highly associated with
HLA-B51 immunogenetically and tend to be involved with chronic
infectious foci, such as tonsillitis and dental caries, by nonpatho-
genic streptococci in the oral cavity. BD patients were suggested
to be hypersensitive to streptococci and we immunohistologically
demonstrated the deposits of streptococcal related antigen at infil-
trated cells which were adhering to the vascular walls in erythema
nodosum (EN)-like lesions. The Japanese Research Group for BD
also demonstrated that BD patients showed greater hypersensitiv-
ity against streptococcal antigens than normal healthy controls and
that the BD symptoms were frequently induced by the skin tests
using these antigens and the treatment of the dental caries. Strep-
tococcus sanguis was dominantly isolated from the infectious foci
and the strain strongly adhered to the epithelial cells of the oral
membrane, which might be correlated with chemotactic activity of
neutrophils in the BD lesions. An attempt at cloning and sequenc-
ing the bes-1 gene of S. sanguis isolated from BD patients was
made and it has been found that the amino acid sequence of the
bes-1 gene has more than 60% of homology with the human
intraocular peptide brn-3b, which is a POU domain expressed in
the retinal ganglion cells. On the other hand, heat shock protein-65
kDa (HSP-65) derived from microbial organisms which had homol-
ogy with human HSP-60 was shown to be cross-reactive to the
serotype of S. sanguis found in BD patients. Recently we recog-
nized the antibody cross-reactivity against human HSP-60 peptide
(336-351), which might stimulate T-lymphocytes of BD patients. In
order to explain more precisely the relationship between S. sanguis
and BD symptoms, we attempted to find bes-1 gene in the various
lesions and to detect the antibodies against both bes-1 synthetic
peptides and recombinant HSP-60/65 of S. sanguis in sera of BD
patients.
Methodology We performed PCR and PCR in situ hybridization
(PCR-ISH) on the samples of BD lesions obtained by punch
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biopsy and controls using nested primers, which amplify the S.
sanguis genomic region coding for bes-1, including the brn-3b
homologous site. We also evaluated the antibody responses
against bes-1 peptides and recombinant HSP-60/65.
Results We detected the presence of bes-1 DNA in the samples
of EN-like eruptions, and oral and genital aphthous lesions by PCR
analysis. PCR-ISH also revealed bes-1 DNA gene located in the
nuclei of the cells adhering to the vessel walls and macrophages
infiltrated in EN-like lesions, whereas the antibodies against both
bes-1 peptides and recombinant HSP-60/65 protein have not
been detected in sera of these patients.
Conclusions The presence of bes-1 DNA in macrophages infil-
trated in the various lesions of BD patients suggests that the infec-
tious foci by S. sanguis in the oral cavity are deeply correlated with
the various lesions in BD patients. It is speculated that the clinical
symptoms appear by the internalization of bes-1 DNA to
macrophages infiltrated, as an extrinsic factor, in BD patients who
are associated with HLA-B51-related gene as an intrinsic factor.
However, it is not clear how S. sanguis infection is correlated with
HLA-B51-related gene as the genetic background in BD patients.
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